Status:
TERMINATED
Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients
Lead Sponsor:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborating Sponsors:
PharmaMar
Conditions:
Soft Tissue Sarcoma
Eligibility:
All Genders
18+ years
Brief Summary
Chemotherapy with Trabectedin is an effective treatment for sarcoma patients in the second line setting or in first line for patients who are deemed unsuitable to receive anthracycline therapy. The pr...
Detailed Description
Chemotherapy with Trabectedin is an effective treatment for sarcoma patients in the second line setting or in first line for patients who are deemed unsuitable to receive anthracycline therapy. Severa...
Eligibility Criteria
Inclusion
- Enrolled participant of the GISAR registry and their sub-studies
- Patient with histologically confirmed soft tissue sarcomas
- Pretreatment with Trabectedin, termination of this therapy regardless of reason
- Planned rechallenge or started rechallenge with Trabectedin in any line of therapy within 2 weeks before inclusion
- Interval between last Trabectedin treatment and Trabectedin rechallenge at least 3 months
Exclusion
- Not able to understand all implications of study participation
- No written informed consent
- Age ≤ 18 years
Key Trial Info
Start Date :
October 31 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 30 2024
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT06050434
Start Date
October 31 2023
End Date
July 30 2024
Last Update
December 1 2025
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
HELIOS KLinikum Bad Saarow
Bad Saarow, Germany
2
HELIOS Klinikum Berlin Buch
Berlin, Germany
3
Frankfurt Universitätsklinikum
Frankfurt am Main, Germany
4
Universitätsmedizin Göttingen
Göttingen, Germany